Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups

Cancer

Volumn 115, Issue 17, 2009, Pages 4021-4029

  Zlobec, Inti ^a   Baker, Kristi ^b,c   Minoo, Parham ^d   Hayashi, Shinichi ^e   Terracciano, Luigi ^a   Lugli, Alessandro ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b MCGILL UNIVERSITY   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Colorectal cancer; Prognosis; Staging; Tumor border configuration

Indexed keywords

AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECTAL NEOPLASMS;

EID: 69249103008     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24450     Document Type: Article

References (22)

1. Quirke P, Williams GT, Ectors N, Ensari A, Piard F, Nagtegaal I. The future of the TNM staging system in colorectal cancer: time for a debate? Lancet Oncol. 2007;8:651-657.
2. Duffy MJ, van Dalen A, Haglund C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43:1348-1360.
3. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313-5327.
4. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet. 1987;1:1303-1306.
5. De Quay N, Cerottini JP, Albe X, Saraga E, Givel JC, Caplin S. Prognosis in Duke's B colorectal carcinoma: the Jass classification revisited. Eur J Surg. 1999;165:588-592.
6. Deans GT, Heatley M, Anderson N, et al. Jass' classification revisited. J Am Coll Surg. 1994;179:11-17.
7. Fisher ER, Robinsky B, Sass R, Fisher B. Relative prognostic value of the Dukes and the Jass systems in rectal cancer. Findings from the National Surgical Adjuvant Breast and Bowel Projects (Protocol R-01). Dis Colon Rectum. 1989;32:944-949.
8. Harrison JC, Dean PJ, el-Zeky F, Vander Zwaag R. From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pathol. 1994;25:498-505.
9. Haslam AC, Pearson JM, Bisset DL, Michie HR, Hobbiss JH. A Dukes/Jass combination-is it more discriminating? Colorectal Dis. 2006;8:418-422.
10. Cianchi F, Messerini L, Palomba A, et al. Character of the invasive margin in colorectal cancer: does it improve prognostic information of Dukes staging? Dis Colon Rectum. 1997;40:1170-1175; discussion 1175-1176.
11. Compton CC. Optimal pathologic staging: defining stage II disease. Clin Cancer Res. 2007;13(22 pt 2):6862s-6870s.
12. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum. 1993;36:627-635.
13. Jass JR, Atkin WS, Cuzick J, et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology. 1986;10:437-459.
14. Efron B, Tibshirani R. An Introduction to the Bootstrap. Boca Raton, FL: CRC Press; 1993.
15. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359:1686-1689.
16. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408-3419.
17. Kohne CH. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Against the proposal. Lancet Oncol. 2006;7:516-517.
18. Sobrero A. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal. Lancet Oncol. 2006;7:515-516.
19. Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020-2029.
20. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638-646.
21. Zlobec I, Lugli A, Baker K, et al. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. J Pathol. 2007;212:260-268.
22. Compton CC. Pathology report in colon cancer: what is prognostically important? Dig Dis. 1999;17:67-79.